Background
Methods
Aim
Population and data collection
Statistical analysis
Results
Patient flow and characteristics
Variable | Total n (%) | Group A n (%) | Group B n (%) | p-value |
---|---|---|---|---|
Gender | ||||
Male | 46 (56.1) | 35 (61.4) | 11 (44) | |
Female | 36 (43.9) | 22 (38.6) | 14 (56) | 0.144 |
Age (years) | ||||
≤ 60 | 22 (26.8) | 17 (29.8) | 5 (20) | |
61–68 | 22 (26.8) | 16 (28.1) | 6 (24) | |
69–74 | 24 (29.3) | 15 (26.3) | 8 (32) | |
≥ 75 | 14 (17.1) | 9 (15.8) | 6 (24) | 0.666 |
Type of liver disease | ||||
No cirrhosis or HCC | 45 (54.9) | 34 (59.6) | 9 (36) | |
Cirrhosis | 35 (42.7) | 23 (40.4) | 14 (56) | |
HCC with cirrhosis | 2 (2.4) | 0 (0) | 2 (8) | 0.025 |
Transient elastography | ||||
None | 7 (8.5) | |||
F0 | 0 (0) | 0 (0) | 0 (0) | |
F1 | 2 (2.4) | 2 (3.9) | 0 (0) | |
F2 | 3 (3.8) | 3 (5.9) | 0 (0) | |
F3 | 33 (40.2) | 29 (56.9) | 3 (13) | |
F4 | 37 (45.1) | 17 (33.3) | 20 (87) | < 0.01 |
HCV Genotype | ||||
1a | 2 (2.4) | 1 (1.7) | 1 (4) | |
1b | 60 (73.3) | 42 (73.7) | 17 (68) | |
2 | 6 (7.3) | 3 (5.3) | 3 (12) | |
2a/2c | 5 (6.1) | 6 (10.5) | 0 (0) | |
3 | 4 (4.8) | 1 (1.7) | 3 (12) | |
4 | 5 (6.1) | 4 (7.1) | 1 (4) | 0.148 |
Co-infections | ||||
None | 81 (98.8) | 56 (98.3) | 25 (100) | |
HIV + | 1 (1.2) | 1 (1.7) | 0 (0) | |
HBsAg +/HIV - | 0 (0) | 0 (0) | (0) | 0.505 |
BMI | ||||
Normal | 23 (28) | 18 (31.6) | 5 (20) | |
Overweight/Obese | 59 (71.0) | 39 (68.4) | 20 (80) | 0.283 |
Risk factors for CV diseasesa | ||||
None | 19 (23.2) | 15 (26.3) | 4 (16) | 0.308 |
Hypertension | 51 (62.2) | 34 (59.6) | 17 (68) | 0.473 |
Diabetes mellitus | 21 (25.6) | 12 (21.1) | 8 (32) | 0.288 |
Smoking habits | 14 (17.1) | 11 (19.3) | 3 (12) | 0.419 |
Previous CV events | 4 (4.8) | 3 (5.3) | 1 (4) | 0.807 |
Comorbiditiesa | ||||
None | 19 (23.2) | 15 (26.3) | 4 (16) | 0.308 |
eGFR < 90 ml/min | 43 (52.4) | 32 (39) | 11 (13.4) | 0.350 |
Osteoporosis | 15 (18.3) | 10 (17.6) | 5 (20) | 0.791 |
Depression | 14 (17.1) | 11 (19.3) | 3 (12) | 0.419 |
Treatment course
Cate | n (%) |
---|---|
Prescribed DAAs | |
SOF + RBV | 10 (12.2) |
SOF + SIM ± RBV | 29 (35.4) |
SOF + LDV ± RBV | 31 (37.8) |
SOF + DCV ± RBV | 12 (14.6) |
Ribavirin | |
Yes | 49 (59.7) |
No | 33 (40.3) |
Ribavirin modification | |
None | 26 (53.1) |
Reduction | 22 (44.9) |
Suspension | 1 (2) |
Adding support drug for anaemia in patients with ribavirin | |
None | 38 (77.6) |
Folic acid | 7 (14.2) |
Erythropoietin | 2 (4.1) |
Folic acid + erythropoietin | 2 (4.1) |
Reason for stopping DAAs | |
End of treatment | 80 (97.6) |
Patient decision | 1 (1.2) |
Virological failure | 1 (1.2) |
Parameters | Group A baseline mean (SD) | Month 1 mean (SD) | End of treatment mean (SD) | 6th month of follow-up mean (SD) | p-value* | Group B baseline mean (SD) | Month 1 mean (SD) | End of treatment mean (SD) | 6th month of follow-up mean (SD) | p-value* |
---|---|---|---|---|---|---|---|---|---|---|
FIB-4 | 3.8 (3.6) | – | – | 2.7 (1.8) | 0.003 | 5.5 (5.3) | – | – | 3.7 (4.7) | < 0.001 |
APRI SCORE | 1.2 (1.1) | – | – | 0.6 (0.9) | < 0.001 | 1.7 (1.8) | – | – | 0.9 (2.1) | 0.002 |
INR | 1.1 (0.2) | – | – | 1.1 (0.1) | 0.111 | 1.1 (0.2) | – | – | 1.1 (0.1) | 0.435 |
α-fetoprotein (ng/mL) | 12.8 (20.9) | – | – | 7.8 (19.3) | < 0.001 | 19.5 (28.9) | – | – | 5.9 (3.1) | 0.014 |
Creatinine (mg/dL) | 0.8 (0.2) | – | – | 0.9 (0.2) | 0.031 | 0.7 (0.1) | – | – | 0.8 (0.1) | 0.032 |
Glucose (mg/dL) | 112 (29) | – | – | 110.5 (30.8) | 0.266 | 128.6 (41.7) | – | – | 119.3 (31.7) | 0.337 |
Haemoglobin (g/dL) | 14.2 (2.2) | – | – | 14.1 (2.1) | 0.551 | 13.6 (1.9) | – | – | 13.9 (1.8) | 0.625 |
Cholesterol (mg/dL) | 155.2 (30.8) | – | – | 163.5 (29.8) | 0.070 | 149.9 (38.1) | – | – | 179.3 (46.2) | 0.003 |
Triglycerides (mg/dL) | 111.25 (46.12) | – | – | 110.96 (46.49) | 0.155 | 112.12 (39.64) | – | – | 100.8 (46.73) | 0.295 |
AST (UI/L) | 59.2 (40.9) | 24.8 (13.3) | 22.9 (9.1) | 25.6 (13.4) | < 0.001 | 68.7 (40.6) | 29.8 (19.7) | 23.8 (8.3) | 24.3 (8.3) | < 0.001 |
ALT (UI/L) | 65. (41.3) | 21.7 (11.4) | 18.3 (6.8) | 20.5 (9.4) | < 0.001 | 69.7 (52.3) | 24 (15.1) | 20.5 (8.5) | 20.3 (10) | < 0.001 |
Platelet (×10 [3]/mL) | 166.8 (65.8) | 183.4 (78.5) | 171.1 (77.5) | 167.1 (61.5) | 0.399 | 139.3 (62.1) | 161.2 (72.3) | 153.9 (65.4) | 150.2 (58.9) | 0.779 |
Total bilirubin (mg/dL) | 0.9 (0.7) | 1.1 (0.7) | 0.9 (0.8) | 0.7 (0.5) | < 0.001 | 1 (0.8) | 1 (0.7) | 0.7 (0.6) | 0.8 (0.5) | < 0.001 |
Ejection Fraction (%) | 56.5 (3.1) | 56.9 (3.5) | 56.6 (2.5) | 56.7 (2.8) | 0.499 | 56.9 (2.9) | 57 (3) | 57.2 (3.2) | 57.4 (3.6) | 0.535 |
GLS (%) | −20.8 (2.8) | −21.4 (2.4) | −20.9 (2.6) | −20.3 (2.6) | 0.031 | −21.1 (2.4) | −20.7 (2.7) | −20.3 (2.8) | −20.1 (2.5) | 0.097 |